Kaleido Biosciences Announces Data from MMT Programs Accepted for Presentation at Upcoming Scientific Conferences

NEXT STORY
Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium
PREV STORY
Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors

Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. ...

author_avatar
NASDAQ Market News

Loxo Oncology Announces First Quarter 2017 Financial Results

– Larotrectinib Late-Breaking Oral Presentation at ASCO Annual Meeting on June 3, 2017 – ...

author_avatar
NASDAQ Market News

OptimizeRx to Launch Real-time Financial Messaging With Modernizing Medicine, Providing Prescription Cost Savings at Point-of-Care

ROCHESTER, Mich. and BOCA RATON, Fla., Dec. 06, 2017 (GLOBE NEWSWIRE) -- OptimizeRx Corp. ...

author_avatar
NASDAQ Market News